The pharmaceutical industry is one of the leaders in terms of the intensity of commercialization of the intellectual activity results (IAR). Its development as a socially significant industry is a priority in the state policy of countries with developing economies, in particular, the countries of the Latin American region (LA). A number of economic conditions for the development of commercialization of the IAR in these countries are similar to the Russian economy. Common barriers to development include dependence on imported substances, inefficient interaction between science and business, lack of public and private investment in R&D, and insufficient development of the intellectual property (IP) institution. At the same time, it is possible to identify common growth drivers: the growth potential of the consumer market, unique natural resources, relatively high scientific potential, and the concentration of R&D in research institutes and universities. The similarity of the conditions helps to suggest that it is possible to adapt the best practices of IAR commercialization formed in the LA, to the Russian economy. The research method used in this article include analyzing published legislative and statistical materials on financial institutions of the LA countries in order to identify problems and experience in overcoming them in the field of commercialization of intellectual property. The analysis of state support for imitation, closed and open models of commercialization of IAR used by pharmaceutical companies in developing economies made it possible to identify successful support mechanisms, as well as positive and negative results of the application of each model. On this basis, as the results of the research recommendations for state support for the commercialization in socially significant industries of the Russian economy are suggested.
